Early Biomarkers as Predictors of Nephrology Trial Trajectory - Pharmaceutical Technology

Faced with slow-moving study endpoints and distant clinical thresholds, nephrology sponsors need earlier insights to support critical development decisions. Faced with slow-moving study endpoints and distant clinical thresholds, nephrology sponsors need earlier, actionable insights to support critical development decisions and major investment milestones. This article explores how biomarkers are reshaping nephrology research, examining the established strategies, emerging tools, and missed opportunities that can accelerate timelines and reduce ambiguity. Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet medical needs, there is an urgent need for safer, more effective and…

Source: Pharmaceutical Technology